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Objective: Patients with visual snow syndrome (VSS) suffer from continuous
(“TV snow-like”) visual disturbance of unknown pathoetiology. In VSS, changes in cortical
excitability in the primary visual cortex and the visual association cortex are discussed,
with recent imaging studies tending to point to higher-order visual areas. Migraine,
especially migraine with aura, is a common comorbidity. In chronic migraine and episodic
migraine with aura but not in episodic migraine without aura, a reduced magnetic
suppression of perceptual accuracy (MSPA) reflects a probably reduced inhibition of the
primary visual cortex. Here we investigated the inhibition of the primary visual cortex
using MSPA in patients with VSS, comparing that with MSPA in controls matched for
episodic migraine.
Methods: Seventeen patients with VSS were compared to 17 age- and
migraine-matched controls. Visual accuracy was assessed by letter recognition and
modulated by transcranial magnetic stimulation delivered to the occipital cortex at
different intervals with respect to the letter presentation (40, 100, and 190 ms).
Results: Suppression of visual accuracy at the 100-ms interval was present without
significant differences between VSS patients and age- and migraine-matched controls
(percentage of correctly recognized trigrams, control: 46.4 ± 34.3; VSS: 52.5 ± 25.4,
p = 0.56).
Conclusions: In contrast to migraine with aura, occipital cortex inhibition, as assessed
with MSPA, may not be affected in VSS.
Keywords: visual snow syndrome, cortical hyperexcitability, magnetic suppression of perceptual accuracy,
migraine, pathophysiology
INTRODUCTION
Patients with visual snow (VS) describe continuous, mostly black and white tiny flickering dots
in their entire visual field, comparable to the old TV-static noise when missing the analog signal.
When accompanied by other visual symptoms such as afterimages (palinopsia), impaired night
vision (nyctalopia), or increased light sensitivity (photophobia), it is called visual snow syndrome
(VSS) (1–3). Its pathophysiology is still under discussion, and although it is highly associated with
migraine with and without aura and may partially overlap with these, recent research strongly
suggests that VS is a distinct disorder (2–5). The visual disturbance sums up to a clinical picture that
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is best explained by dysfunction of the higher-order visual cortex.
Consistently, fluorodeoxyglucose-positron emission tomography
(PET) investigations showed hypermetabolism in the lingual
gyrus, an area of the higher visual association cortex (3, 6).
Importantly, these findings from functional neuroimaging were
confirmed by voxel-based morphometry by two independent
groups which demonstrated increased gray matter volume in
the same cortical area (6, 7). A possible neurophysiological
correlate of the involvement of higher visual areas could be
the significantly prolonged latency of the late N145 potentials
with normal P100 potentials in visual evoked potentials (4).
However, the picture is likelymore complex with studies pointing
to a dysfunction of the primary visual cortex, considering
thalamocortical dysrhythmia as the origin of VSS (8, 9) and
demonstrating alterations also in non-visual, acoustic, and limbic
areas (6).
Here we used magnetic suppression of perceptual accuracy
(MSPA) to further elucidate the role of the primary visual
cortex or at least its inhibition in VSS. Reduced MSPA reflects
reduced inhibition of the primary visual cortex, which is seen
in chronic migraine and episodic migraine with aura, but not
in episodic migraine without aura (10). Reduced MSPA in
VSS would therefore argue for a decreased local inhibition
of the primary visual cortex similar to episodic migraine
with aura.
MATERIALS AND METHODS
The study was conducted in accordance with the Declaration of
Helsinki and approved by the local ethics committee (227-15).
All patients gave written informed consent. The results of the
study were presented in preliminary format at the International
Headache Conference 2017 (11).
Subjects
For recruitment, the study was advertised in social media
with support from the self-help group on VS, “Eye on Vision
Foundation” (http://www.eyeonvision.org/). We first assessed
the eligibility of interested patients during telephone interviews
conducted by a headache specialist familiar with VSS. The
interview was cross-checked by a second headache specialist.
Inclusion criteria were age ≥ 18 years and presence of VSS
(subtype black and white dots) in accordance with the criteria
published previously (2). Exclusion criterion was intake of any
illicit drugs currently or within 2 weeks prior to the onset of VSS.
BrainMRI was normal in all subjects. Later, the VSS patients were
examined at presentation by one of the twomentioned specialists.
Of medications known to possibly affect cortical excitability,
only one patient was on lamotrigine and three patients were on
mirtazapine. Travel expenses were reimbursed, and no further
payment was made for study participation. Patients with VSS
were compared to age- and migraine-matched subjects.
Measurement of MSPA
MSPA was measured according to our previous work (10).
To summarize, three-letter sequences (so-called trigrams) were
presented for 30ms on a monitor in front of the subjects. They
were instructed to read the letters aloud from left to right. In a
first step, training runs were performed to adjust contrast in a
manner that ∼80% of the letters could be recognized correctly
by the subject without transcranial magnetic stimulation (TMS)
intervention. In a second step, the experiment was started
by presenting a series of 54 trigrams, followed each by a
TMS pulse (output of at least 70% of the possible maximum
output, Magstim 200, The MagStim Company Ltd, Whitland,
UK) via a 90-mm circular coil to the occipital cortex in
randomized intervals of 40, 100, or 190ms in regard to the
trigram presentation. The time between the start of trigram
presentation and TMS pulse delivery is called stimulus onset
asynchrony (SOA). Later, the percentage of correctly recognized
trigrams was calculated for each SOA interval. All subjects were
measured interictally; as corroborated by telephone contact, no
subject reported a migraine attack or aura within 2 days after
the experiment.
Statistical Analysis
Statistical analysis was done using SPSS 25 (IBM Corp. Released
2017. IBM SPSS Statistics for Windows, version 25.0.0.1, 32-bit-
version, Armonk, NY: IBM Corp.). Statistical significance was
assumed at p ≤ 0.05. The demographics of the groups were
compared using chi-square test.
ANOVA was used for MSPA comparison (within-subject
factor: SOA, between-subject factor: group). Where ANOVA was
significant (p ≤ 0.05), t-test with Bonferroni correction was used
for post hoc analysis.
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Seventeen patients with visual snow syndrome (six females and
11 males; mean age, 30.0 ± 10.8 years; 12 with comorbid
migraine, seven of them also with typical migraine aura) were
compared to 17 control subjects (C) (14 females and three
males; mean age, 28.3 ± 8.2 years; 12 with comorbid migraine,
none of them with typical migraine aura). The groups did differ
in gender (χ = 7.77 p = 0.005) and aura (χ = 8.82 p =
0.003), but not in migraine (χ = 0, p = 1) and age χ =
16.87, p = 0.66. For more information on study population,
see the Supplementary Table 1. If not stated otherwise, the
term “controls” describes the group of age- and migraine-
matched subjects.
MSPA
The MSPA profiles of patients with VSS and migraine-matched
controls can be seen in Figure 1 and Table 1.
There was a significant main effect of SOA interval
(rmANOVA: Greenhouse–Geisser F 31.75, p ≤ 0.01) with a
significant suppression of visual accuracy at 100ms compared
to 40 and 190ms. There was no significant main effect
of group (rmANOVA: F 0.70, p = 0.47). Additionally, we
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FIGURE 1 | MSPA profiles of subjects with visual snow syndrome and migraine-matched control group at the three SOA intervals. There was a significant change with
the SOA interval but no group difference. SOA, stimulus onset asynchrony.
TABLE 1 | Mean percentage of correctly detected trigrams at the three different
stimulus onset asynchrony (SOA) intervals (40, 100 and 190ms).
SOA Average percentage correct
(mean ± SD)
Visual snow syndrome Control
40ms 70.70 ± 14.88 70.26 ± 26.53
100ms 52.51 ± 25.41 46.40 ± 34.26
190ms 74.95 ± 10.08 76.91 ± 22.62
performed an explorative subgroup analysis beginning with
comparing the same control group only with VSS patients
without migraine aura, showing almost identical percentages of
correctly recognized trigrams at 100ms (C: 46.40 ± 34.26 vs.
VSS: 46.67 ± 27.99), again without significant group differences
(rmANOVA: F 0.261, p= 0.77).
Afterwards, to understand the effect of aura in our VSS
group itself, we compared VSS patients with migraine with aura
(VSSMwA; n = 7) and VSS patients with migraine without aura
(VSSMwoA; n = 5). There was again a significant main effect
of SOA interval (rmANOVA: Greenhouse–Geisser F 6.31, p ≤
0.05) with a significant suppression of visual accuracy at 100ms
(VSSMwoA: 48.2± 31.89 vs. VSSMwA: 60.85± 20.21) compared
to 40 and 190ms, but also no significant main effect of group
(rmANOVA: F 0.40, p= 0.57).
DISCUSSION
The main result of this study is that magnetic suppression of
perceptual accuracy is not reduced in visual snow syndrome
when compared to controls matched for migraine. In this
respect, VSS differs frommigraine with aura (12). The significant
suppression at 100ms is comparable instead to that of patients
with migraine without aura and controls without migraine
(10). Previous work of Aurora and Mulleners showed that
healthy controls exhibited the largest suppression at 100ms
SOA, followed by migraine patients without aura, while chronic
migraine patients and episodic migraineurs with aura showed
the least suppression (12, 13). Consistently, within the VSS
group, subjects with migraine with aura showed a smaller MSPA
compared to those without aura. However, the difference was not
significant, maybe due to the small sample sizes in the subgroups.
It has been discussed that a reduced MSPA reflects a higher
cortical excitability due to a deficiency of intracortical inhibition
of the primary visual cortex (12). This would facilitate the
initiation of cortical spreading depression, resulting in an attack
of migraine with visual aura, but apparently playing a minor role
in migraineurs without aura (10, 14).
Visual snow syndrome is thought to involve cortical
hyperexcitability or a lack of inhibition. The present results
suggest that, at least for our collective, such hyperexcitability
does not seem to arise from the primary visual cortex. From
the clinical description, the typical visual phenomena seem to
be best explained by a dysfunction of higher-order visual cortex.
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This is supported by overlapping morphological and functional
correlates in the visual association cortex in PET and MRI (3, 6)
as well as alterations in the late visual evoked potentials (4).
LIMITATIONS
One limitation of the study is the lack of matching for gender,
but to the best of our knowledge, there is no evidence of
sex differences in MSPA. Nevertheless, an influence cannot be
excluded. Another limitation is the lack of matching for aura,
but based on our explorative subgroup analysis irrespective of
inclusion or exclusion of the aura patients in the VSS group,
the results remained unchanged. Additionally, it should be
mentioned that, in the VSS group, the disability caused by
headache measured byMigraine Disability Assessment was lower
compared to the migraine-matched controls, as we matched for
comorbidity and not severity. Lastly, we could have added a
healthy control group without comorbid migraine and give more
details on clinical data.
CONCLUSION
This study demonstrates that magnetic suppression of perceptual
accuracy, in contrast to the situation in migraine with aura, is
not reduced in VSS compared to migraine-matched controls.
Therefore, although hyperexcitability apparently occurs in both
VSS and migraine aura, the locations seem to be different. The
primary visual cortex might not be the main location in VSS.
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